Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Aug 24;11:373. doi: 10.1186/1471-2407-11-373

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright ©2011 Fiegl et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Progression-Free Survival related to response. Kaplan-Meier plot illustrating progression-free survival (PFS) in patients with metastasized breast cancer who received liposomal pegylated doxorubicin (PLD) monotherapy. Plotted according to radiographic response after completion of PLD, median PFS was 10.0 months for patients with complete (CR) or partial rememission (PR), 11.9 months with stable disease (SD), 2.8 months with progressive disease (PD), and 2.4 months in which response could not be evaluated (NE), which was significantly different when pooled over strata (P < 0.001). Pairwise comparisons showed no PFS difference between patients with CR/PR and SD.